Most Ayurveda marketing in India fails on a single word, and the word is "cure".
Not because patients dislike it. Because the sentence a clinic most wants to write is, in a large number of cases, prohibited by a law passed in 1954 and still enforced. Every plan that starts with the claim and works backwards to the rules ends up rewriting itself, usually after a notice.
Start the other way round. Work out what you are allowed to say, then find the version of that which is still persuasive. There is more room than clinic owners assume — it just is not where they look first.
You are probably in one of two different businesses
The rules diverge sharply depending on what you sell, and a lot of confusion comes from mixing them.
If you manufacture or sell an Ayurvedic, Siddha or Unani medicine, you are regulated as a drug: licensing under the Drugs and Cosmetics Act, 1940 and its Rules, and a separate set of requirements around advertising those products.
If you run a clinic — consultations, panchakarma, therapy programmes — you are selling a professional service. Your constraints come from the practitioner conduct rules, the advertising statute below, and the general consumer-protection machinery.
Most Ayurveda businesses do both, and then write one set of copy for both. That is where the trouble starts.
The Drugs and Magic Remedies Act is the one that bites
The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 prohibits advertising any drug or remedy as a treatment, prevention or cure for a schedule of specified conditions. The Schedule covers exactly the things clinics most want to advertise: cancer, diabetes, tuberculosis, heart disease, epilepsy, paralysis, leprosy, sexual impotence, female sterility, disorders of menstrual flow, cataract, glaucoma, deafness, goitre and a long list besides.
The Act also prohibits advertisements that are misleading in a material particular, that make a false impression about a remedy's nature, or that suggest a therapeutic effect it does not have. It applies to advertisements in any medium, which includes your website, your Instagram grid and your Google Ads copy.
Read the Schedule before you write anything. Not a summary of it — the actual list, from the bare Act. It is short, it is public, and it will settle most of your copy arguments in ten minutes.
Rule 170 is gone, and a lot of agency advice has not caught up
Rule 170 of the Drugs and Cosmetics Rules, 1945 was inserted by the Drugs and Cosmetics (Fifth Amendment) Rules, 2018. It required advertisements for Ayurveda, Siddha and Unani drugs to carry a unique identification number issued by the state licensing authority, with the advertisement approved in advance.
It no longer applies. The Ministry of AYUSH omitted the rule by the Drugs (Fourth Amendment) Rules, 2024, notified on 1 July 2024. The Supreme Court stayed that omission on 27 August 2024 in the proceedings in Indian Medical Association v. Union of India, the matter arising out of the misleading-advertisement case. On 11 August 2025 the Court vacated the stay and disposed of the petition, holding that the reliefs sought had substantially been achieved. Rule 170 stands omitted.
Two things follow. First, if a proposal or a compliance checklist you have been given still requires a Rule 170 approval number, it was written before August 2025 and you should ask what else in it is out of date.
Second — and this is the part people get wrong — the removal of an approval mechanism is not the removal of the underlying prohibition. The 1954 Act still applies in full. So does the consumer-protection machinery. What has gone is a pre-clearance step, not the rule about what you may claim. If anything, the absence of a stamp means there is nobody between you and a complaint.
Clinic service advertising — a consultation, a therapy programme — is a different question from product advertising in any case, and conflating the two is the most common mistake we see in AYUSH accounts.
Who regulates the practitioner
Ayurveda practitioners in India register under the National Commission for Indian System of Medicine, established by the NCISM Act, 2020, which replaced the Central Council of Indian Medicine. Their conduct is governed by the National Commission for Indian System of Medicine (Ethics and Registration) Regulations, 2023, notified on 29 December 2023, which superseded the 1982 conduct regulations for practitioners of Indian medicine.
Modern-medicine practitioners come under the National Medical Commission. Their conduct code is the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002, read since 6 October 2026 with the NMC's ethical advertising guidelines. Those guidelines also cover hospitals and medical institutions in any recognised system of medicine, so an integrative hospital falls inside them even where its Ayurveda practitioners answer to NCISM individually. Our NMC guidelines hub summarises them.
That distinction matters if you employ both. The general principle across both systems is the same: you may state facts about the practitioner — name, qualifications, registration, specialisation, address, timings — and you may not solicit, self-praise, or claim superiority over others.
Then there is the Advertising Standards Council of India. ASCI is self-regulatory but its decisions carry weight with platforms and broadcasters, and its chapters on misleading advertising and on healthcare apply directly to this category. Our summary of ASCI compliance for healthcare advertising covers what gets flagged in practice. On top of that sits the Central Consumer Protection Authority, whose guidelines on misleading advertisements and endorsements give a regulator with real teeth a route into the same conduct.




